A detailed history of Darwin Advisors, LLC transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Darwin Advisors, LLC holds 209 shares of GILD stock, worth $19,451. This represents 0.0% of its overall portfolio holdings.

Number of Shares
209
Holding current value
$19,451
% of portfolio
0.0%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 08, 2024

BUY
$66.59 - $83.99 $13,917 - $17,553
209 New
209 $17,000
Q3 2020

Oct 16, 2020

SELL
$62.1 - $78.08 $2.51 Million - $3.16 Million
-40,463 Closed
0 $0
Q2 2020

Aug 06, 2020

BUY
$72.34 - $84.0 $2.89 Million - $3.36 Million
39,951 Added 7802.93%
40,463 $3.11 Million
Q1 2020

May 01, 2020

BUY
$62.63 - $80.22 $32,066 - $41,072
512 New
512 $38,000
Q1 2018

May 08, 2018

SELL
$72.84 - $88.8 $1.76 Million - $2.15 Million
-24,163 Closed
0 $0
Q4 2017

Feb 13, 2018

BUY
$71.15 - $83.52 $1.72 Million - $2.02 Million
24,163
24,163 $1.73 Million

Others Institutions Holding GILD

About GILEAD SCIENCES, INC.


  • Ticker GILD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,253,369,984
  • Market Cap $117B
  • Description
  • Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...
More about GILD
Track This Portfolio

Track Darwin Advisors, LLC Portfolio

Follow Darwin Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Darwin Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Darwin Advisors, LLC with notifications on news.